Expertise in
14
conditions

Dr. Anthony F. Shields

Hematology Oncology | Hematology | Oncology
University Physician Group
4100 John R St, 
Detroit, MI 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Expertise in
14
conditions
University Physician Group
4100 John R St, 
Detroit, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Anthony Shields is a Hematologist Oncology specialist and a Hematologist in Detroit, Michigan. Dr. Shields is highly rated in 14 conditions, according to our data. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Anal Cancer, and Pseudomyxoma Peritonei. Dr. Shields is currently accepting new patients.

His clinical research consists of co-authoring 155 peer reviewed articles and participating in 24 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MI
Hospital Affiliations
Karmanos Cancer Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

UNIVERSITY PHYSICIAN GROUP
4100 John R St, Detroit, MI 48201

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

24 Clinical Trials

A Phase I/II Study of M3814 and Avelumab in Combination With Hypofractionated Radiation in Patients With Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
A Phase I/II Study of M3814 and Avelumab in Combination With Hypofractionated Radiation in Patients With Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Enrollment Status: Recruiting
Publish Date: October 10, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Avelumab, Peposertib
Study Phase: Phase 1/Phase 2
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Enrollment Status: Recruiting
Publish Date: July 14, 2025
Intervention Type: Drug, Biological
Study Drugs: Fluorouracil, Irinotecan, Irinotecan hydrochloride, Leucovorin, Leucovorin calcium, Paclitaxel, Ramucirumab
Study Phase: Phase 2
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders
Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Other
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
Enrollment Status: Completed
Publish Date: September 16, 2025
Intervention Type: Biological, Drug
Study Drugs: Olaparib, Ramucirumab
Study Phase: Phase 1/Phase 2
Study of the Effects of Dexamethasone on Non-Small Cell Lung Cancer Using [F-18] FLT for Imaging With Positron Emission Tomography (PET)
Study of the Effects of Dexamethasone on Non-Small Cell Lung Cancer Using [F-18] FLT for Imaging With Positron Emission Tomography (PET)
Enrollment Status: Completed
Publish Date: August 22, 2025
Intervention Type: Procedure, Device, Other, Drug
Study Phase: Not Applicable
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Enrollment Status: Completed
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drugs: INCAGN01876, Nivolumab, Ipilimumab
Study Phase: Phase 1/Phase 2
A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 09, 2025
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2025
Intervention Type: Drug, Other
Study Drugs: Capecitabine, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 2/Phase 3
A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer
A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer
Enrollment Status: Completed
Publish Date: May 02, 2025
Intervention Type: Drug
Study Drugs: LY2880070, Gemcitabine
Study Phase: Phase 1/Phase 2
A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
Enrollment Status: Active_not_recruiting
Publish Date: April 29, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Monitoring Telotristat Ethyl Inhibition of Tryptophan Hydroxylase (TPH) in Neuroendocrine Tumors Using ?-[11C]Methyl-L-tryptophan (AMT)-PET
Monitoring Telotristat Ethyl Inhibition of Tryptophan Hydroxylase (TPH) in Neuroendocrine Tumors Using ?-[11C]Methyl-L-tryptophan (AMT)-PET
Enrollment Status: Completed
Publish Date: April 10, 2025
Intervention Type: Procedure, Other, Drug
Study Drug: Telotristat Etiprate
Study Phase: Phase 2
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 3
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2025
Intervention Type: Drug
Study Phase: Phase 3
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1, Open-Label, Non-randomized, Dose-Escalating Safety, Tolerability, and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors
A Phase 1, Open-Label, Non-randomized, Dose-Escalating Safety, Tolerability, and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 05, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
Enrollment Status: Completed
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drug: 89Zr-Df-IAB22M2C
Study Phase: Phase 2
A Confirmatory, Prospective, Open-label, Multi-centre Phase 3 Study to Evaluate Diagnostic Performance of Zirconium-labelled Girentuximab to Non-invasively Detect ccRCC by PET/CT Imaging in Patients With Indeterminate Renal Masses
A Confirmatory, Prospective, Open-label, Multi-centre Phase 3 Study to Evaluate Diagnostic Performance of Zirconium-labelled Girentuximab to Non-invasively Detect ccRCC by PET/CT Imaging in Patients With Indeterminate Renal Masses
Enrollment Status: Completed
Publish Date: May 17, 2024
Intervention Type: Diagnostic test
Study Phase: Phase 3
A Phase 1, Multicenter, Open-Label Study of SQZ-AAC-HPV as Monotherapy and in Combination With Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
A Phase 1, Multicenter, Open-Label Study of SQZ-AAC-HPV as Monotherapy and in Combination With Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: February 23, 2024
Intervention Type: Drug, Biological
Study Drugs: SQZ-AAC-HPV, Ipilimumab, Nivolumab
Study Phase: Phase 1
Phase Ib Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330), Gemcitabine and Nab-Paclitaxel and Phase II Study of Gemcitabine and Selinexor in Patients With Metastatic Pancreatic Cancer
Phase Ib Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330), Gemcitabine and Nab-Paclitaxel and Phase II Study of Gemcitabine and Selinexor in Patients With Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug, Other
Study Drugs: Gemcitabine hydrochloride, Selinexor, Nab-paclitaxel
Study Phase: Phase 1/Phase 2
Clinical Data Collection for Initial Evaluation of SoftVue: a Novel Ultrasound Breast Scanner
Clinical Data Collection for Initial Evaluation of SoftVue: a Novel Ultrasound Breast Scanner
Enrollment Status: Completed
Publish Date: May 26, 2022
Intervention Type: Other, Procedure
Study Phase: Not Applicable
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Multi-center Study of hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard Therapy
A Multi-center Study of hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard Therapy
Enrollment Status: Completed
Publish Date: November 19, 2018
Intervention Type: Biological
Study Phase: Phase 1
View 22 Less Clinical Trials

155 Total Publications

Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (alliance).
Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (alliance).
Journal: Journal of the National Cancer Institute
Published: June 20, 2025
Similar Doctors
Shirish M. Gadgeel
Expertise in
15
conditions
Dr. Shirish M. Gadgeel
Oncology | Hematology Oncology | Hematology
Expertise in
15
conditions
Dr. Shirish M. Gadgeel
Oncology | Hematology Oncology | Hematology

Henry Ford Health System

2799 W Grand Blvd, 
Detroit, MI 
 (1.8 miles away)
313-916-2600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Shirish Gadgeel is an Oncologist and a Hematologist Oncology provider in Detroit, Michigan. Dr. Gadgeel is highly rated in 15 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Squamous Cell Lung Carcinoma, EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Gadgeel is currently accepting new patients.

Expertise in
26
conditions
Dr. Jeffrey A. Zonder
Hematology Oncology | Hematology | Oncology
Expertise in
26
conditions
Dr. Jeffrey A. Zonder
Hematology Oncology | Hematology | Oncology

University Physician Group

4100 John R St, 
Detroit, MI 
 (0.1 miles away)
800-527-6266
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Zonder is a Hematologist Oncology specialist and a Hematologist in Detroit, Michigan. Dr. Zonder is highly rated in 26 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Primary Amyloidosis, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Vertebroplasty. Dr. Zonder is currently accepting new patients.

Expertise in
12
conditions
Dr. Hirva M. Mamdani
Hematology Oncology | Hematology | Oncology
Expertise in
12
conditions
Dr. Hirva M. Mamdani
Hematology Oncology | Hematology | Oncology

Barbara Ann Karmanos Cancer Institute

4100 John R St, 
Detroit, MI 
 (0.1 miles away)
800-527-6266
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Hirva Mamdani is a Hematologist Oncology specialist and a Hematologist in Detroit, Michigan. Dr. Mamdani is highly rated in 12 conditions, according to our data. Her top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and Pleuropulmonary Blastoma. Dr. Mamdani is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shields's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 49 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile